Table 3.
Associations between PAM50 subtypes and hypoxia signatures with breast cancer outcomes: Multiple regression survival analysis*
| Disease-free survival (N = 295 relapse events)* |
Breast cancer survival (N = 212 breast cancer deaths)* |
|
|---|---|---|
| PAM50 subtypea | HR (95% CI) | HR (95% CI) |
| Luminal A (ref) | 1.0 | 1.0 |
| Basal | 1.24 (0.87, 1.78) | 1.01 (0.65, 1.55) |
| Her2 | 0.98 (0.65, 1.49) | 0.91 (0.56, 1.49) |
| Luminal B | 1.60 (1.19, 2.13) | 1.68 (1.20, 2.35) |
| Model comparison: clinical vs (PAM50 + clinical) | ||
| Likelihood ratio test: Chi square statistic | 11.7 | 12.9 |
| Degrees of freedom | 3 | 3 |
| P-value | 0.009 | 0.005 |
| VEGF13 signatureb | ||
| Low (ref) | 1.00 | 1.00 |
| Medium | 1.33 (0.99, 1.78) | 1.27 (0.90, 1.79) |
| High | 1.48 (1.08, 2.02) | 1.41 (0.98, 2.03) |
| Model comparison: (PAM50 + clinical) vs (PAM50 + clinical +VEGF13) | ||
| Likelihood ratio test: chi square statistic | 6.2 | 3.6 |
| Degrees of freedom | 2 | 2 |
| P-value | 0.04 | 0.16 |
| VEGF15 signatureb | ||
| Low (ref) | 1.00 | 1.00 |
| Medium | 0.92 (0.68, 1.24) | 0.92 (0.65, 1.31) |
| High | 1.33 (0.99, 1.78) | 1.33(0.94,1.87) |
| Model comparison: (PAM50 + clinical) vs (PAM50 + clinical +VEGF15) | ||
| Likelihood ratio test: chi square statistic | 6.7 | 4.8 |
| Degrees of freedom | 2 | 2 |
| P-value | 0.03 | 0.09 |
*Subjects who were classified as normal-like subtype were excluded from this analysis
aModel adjusted for age at diagnosis, tumor grade, tumor stage
bModel adjusted for age at diagnosis, tumor grade, tumor stage, PAM50 subtype